BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22087308)

  • 1. DNA damage stress and inhibition of Jak2-V617F cause its degradation and synergistically induce apoptosis through activation of GSK3β.
    Nagao T; Oshikawa G; Wu N; Kurosu T; Miura O
    PLoS One; 2011; 6(11):e27397. PubMed ID: 22087308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the PI3K/Akt/GSK3 pathway downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD downregulates DNA damage-induced Chk1 activation as well as G2/M arrest and prominently enhances induction of apoptosis.
    Kurosu T; Nagao T; Wu N; Oshikawa G; Miura O
    PLoS One; 2013; 8(11):e79478. PubMed ID: 24260231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Akt activation through the phosphorylation of erythropoietin receptor at tyrosine 479 is required for myeloproliferative disorder-associated JAK2 V617F mutant-induced cellular transformation.
    Kamishimoto J; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2011 May; 23(5):849-56. PubMed ID: 21255641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Critical roles of Myc-ODC axis in the cellular transformation induced by myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Sumi K; Kasahara T; Tago K
    PLoS One; 2013; 8(1):e52844. PubMed ID: 23300995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
    Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
    J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tago K; Abe M; Sonoda Y; Kasahara T
    J Biol Chem; 2010 Feb; 285(8):5296-307. PubMed ID: 20028972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Analysis of oncogenic signaling pathway induced by a myeloproliferative neoplasm-associated Janus kinase 2 (JAK2) V617F mutant].
    Funakoshi-Tago M
    Yakugaku Zasshi; 2012; 132(11):1267-72. PubMed ID: 23123718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-G turns off erythropoietin receptor signaling through JAK2 and JAK2 V617F dephosphorylation: clinical relevance in polycythemia vera.
    Menier C; Guillard C; Cassinat B; Carosella ED; Rouas-Freiss N
    Leukemia; 2008 Mar; 22(3):578-84. PubMed ID: 18059484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
    Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
    Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of JAK2-V617F by components of heterodimeric cytokine receptors.
    Pradhan A; Lambert QT; Griner LN; Reuther GW
    J Biol Chem; 2010 May; 285(22):16651-63. PubMed ID: 20363735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine-phosphorylated SOCS3 negatively regulates cellular transformation mediated by the myeloproliferative neoplasm-associated JAK2 V617F mutant.
    Funakoshi-Tago M; Tsuruya R; Ueda F; Ishihara A; Kasahara T; Tamura H; Tago K
    Cytokine; 2019 Nov; 123():154753. PubMed ID: 31255914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
    Fiskus W; Verstovsek S; Manshouri T; Rao R; Balusu R; Venkannagari S; Rao NN; Ha K; Smith JE; Hembruff SL; Abhyankar S; McGuirk J; Bhalla KN
    Clin Cancer Res; 2011 Dec; 17(23):7347-58. PubMed ID: 21976548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells.
    Umezawa Y; Kurosu T; Akiyama H; Wu N; Nogami A; Nagao T; Miura O
    Oncotarget; 2016 Jul; 7(28):44448-44461. PubMed ID: 27286446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes.
    Pecquet C; Diaconu CC; Staerk J; Girardot M; Marty C; Royer Y; Defour JP; Dusa A; Besancenot R; Giraudier S; Villeval JL; Knoops L; Courtoy PJ; Vainchenker W; Constantinescu SN
    Blood; 2012 May; 119(20):4625-35. PubMed ID: 22378845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor.
    Quintás-Cardama A; Manshouri T; Estrov Z; Harris D; Zhang Y; Gaikwad A; Kantarjian HM; Verstovsek S
    Invest New Drugs; 2011 Oct; 29(5):818-26. PubMed ID: 20372971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. JAK2, the JAK2 V617F mutant and cytokine receptors.
    Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
    Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
    Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
    J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 V617F stimulates proliferation of erythropoietin-dependent erythroid progenitors and delays their differentiation by activating Stat1 and other nonerythroid signaling pathways.
    Shi J; Yuan B; Hu W; Lodish H
    Exp Hematol; 2016 Nov; 44(11):1044-1058.e5. PubMed ID: 27473563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.